NCT,Study title,Status,Location,Target population,Study start date,Sample size,Modality
NCT04385173,A Pilot Study of Chimeric Antigen Receptor (CAR) T Cells Targeting B7-H3 Antigen in Treating Patients With Recurrent and Refractory Glioblastoma,Unknown,China,Recurrent or refractory glioblastoma,"June 1, 2020",12,Chimeric antigen receptor therapy
NCT05241392,"An Open, Single-arm, Phase 1 Study to Evaluate the Safety/Preliminary Effectiveness and Determine the Maximal Tolerated Dose of B7-H3-targeting CAR-T Cell Therapy in Treating Recurrent Glioblastomas",Recruiting,China,Recurrent glioblastoma,"January 27, 2022",30,Chimeric antigen receptor therapy
NCT04077866,B7-H3-Targeted Chimeric Antigen Receptor (CAR) T Cells in Treating Patients With Recurrent or Refractory Glioblastoma,Recruiting,China,Recurrent or refractory glioblastoma,"May 1, 2022",40,Chimeric antigen receptor therapy
NCT05366179,Phase I Study of Intraventricular Infusion of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors (CAR) in Subjects With Recurrent or Refractory Glioblastoma,Not yet recruiting,USA,Recurrent or refractory glioblastoma,August 2022,36,Chimeric antigen receptor therapy
NCT05474378,Phase I Clinical Trial of Locoregionally (LR) Delivered Autologous B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Adults With Recurrent Glioblastoma Multiforme (GBM),Recruiting,USA,Recurrent glioblastoma,"July 12, 2022",39,Chimeric antigen receptor therapy